About: How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 28 September 2010

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2010 (ast) наукова стаття, опублікована у вересні 2010 (uk) scientific article published on 28 September 2010 (en) مقالة علمية نشرت في 28 سبتمبر 2010 (ar)
publication date	wds:Q37793837-82DC49BB-E119-407E-85A8-162D191C08EF wds:Q37793837-E8A1B6D5-70BA-48C8-8D78-8F945FF18B4D
publication date	2010-09-28 00:00:00Z (xsd:dateTime) 2010-10-12 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37793837-7AA915DF-FAED-44CF-A43E-F039156739A6
language of work or name	English
exact match	wds:Q37793837-31EB079D-A750-438E-8B28-8BBFB47B694A
exact match	https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605912
cites work	wds:Q37793837-0156585A-9614-4DF6-ADBD-BB7BE13F6A1A wds:Q37793837-03216B83-21DC-4045-BAEB-EE9DE3A7CEF8 wds:Q37793837-052B0B13-49C1-4222-BDCB-72875905FA69 wds:Q37793837-10D459BB-5115-4FB5-BCD1-3E35D834BC07 wds:Q37793837-11A6489D-9CEC-4127-94C4-92AB8C2EB93A wds:Q37793837-23B95962-7FE6-4A4C-B4E5-9539F1278C2D wds:Q37793837-3575FD0C-DDD0-4B13-9450-C8F350079C85 wds:Q37793837-43363346-991D-4DCE-88B0-D1B89F0B73C1 wds:Q37793837-44D6EE98-EF3D-4398-B682-1FB22A748237 wds:Q37793837-54B59EE4-0F2F-4598-93A7-BE2D1B4234A0 wds:Q37793837-5C1691CE-811E-4DF9-9F2A-3B313F8E7953 wds:Q37793837-664C1564-3602-496C-9802-91C282D15B15 wds:Q37793837-6C18ABDB-4E6B-4F82-9996-00EFEB862C9B wds:Q37793837-7AB84ADC-CD25-4CD1-A7D4-A76D8A5FFE11 wds:Q37793837-8211DBB9-E8E6-4F4D-8417-539336467DD8 wds:Q37793837-991079CE-BDF2-43A9-AFA1-1F078C5D2718 wds:Q37793837-A1690D31-8F9E-4199-AF42-EEE27A22ACDB wds:Q37793837-A24C65CB-1A0D-4612-B62D-9D5CB1DA6BA4 wds:Q37793837-A3FB880B-8BEF-4558-AD46-AA927FCA4C2A wds:Q37793837-AA1D616B-EAB8-45D9-9222-1ADE27160BF7 wds:Q37793837-AACC31CD-679A-4A75-B593-2510373FAE40 wds:Q37793837-AEFFD500-DB72-438D-AC24-A5D36CC32F69 wds:Q37793837-B2E123AB-6CAB-4E35-8AAC-020DA2982919 wds:Q37793837-BFD8DC7B-C666-4E51-A05C-34DEA537901B wds:Q37793837-C0855309-D748-40B3-80A3-F3ABA8EAA930 wds:Q37793837-C1C2F4A5-5FFC-4E97-A5E3-D0695C47A474 wds:Q37793837-C2C0BEB4-57A3-4F23-BBAA-99278C4947B9 wds:Q37793837-D3E6EE73-154A-49EE-9787-56B879BF23DD wds:Q37793837-DAA7164D-86D3-424A-BA5A-05FDB716AD03 wds:Q37793837-DB068A4D-A73A-4747-90E6-F77E0777AF47 wds:Q37793837-DFA0E571-4636-48B2-8734-B5FB7F433621 wds:Q37793837-DFBDAA6A-2F19-457D-BC53-ABDC936DCAFE wds:Q37793837-EAD4AD60-A3FC-40F5-AAA5-2A25FF7C093A wds:Q37793837-EDFD00CE-64AB-4AC7-A94D-A93268B3B72E wds:Q37793837-F98DFF20-2AFA-4E05-9F35-F0B09EDD2DE6 wds:Q37793837-FC573BC3-DCD6-435F-A957-6D415A75F5D6
cites work	Multidrug resistance in cancer: role of ATP-dependent transporters Explaining the high mutation rates of cancer cells to drug and multidrug resistance by chromosome reassortments that are catalyzed by aneuploidy Circumventing Resistance to Kinase-Inhibitor Therapy Tumor heterogeneity: causes and consequences A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Refractoriness to antivascular endothelial growth factor treatment: role of myeloid cells Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. THE GENETICS OF BREAST CANCER SUSCEPTIBILITY Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Aneuploidy acts both oncogenically and as a tumor suppressor Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Genetic instabilities in human cancers Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib Resistance to therapy caused by intragenic deletion in BRCA2 Cancer as an evolutionary and ecological process The clonal evolution of tumor cell populations Mutator phenotype may be required for multistage carcinogenesis A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. The mutation rate and cancer Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing Adaptive therapy. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Cancer genome sequencing--an interim analysis. Detection of mutations in EGFR in circulating lung-cancer cells Chromosomal instability determines taxane response Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia The genetic origin of drug resistance in neoplasms: implications for systemic therapy. Evolutionary dynamics of mutator phenotypes in cancer: implications for chemotherapy Clonal Origin of Human Tumors Random mutations, selected mutations: A PIN opens the door to new genetic landscapes
rdfs:label	How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine (en) How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine (nl)
skos:prefLabel	How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine (en)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software